| Sean S Russell, MD | |
|
222 N 7th St, Bismarck, ND 58501-4436 | |
| (701) 323-6000 | |
| (701) 323-5369 |
| Full Name | Sean S Russell |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 36 Years |
| Location | 222 N 7th St, Bismarck, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750493052 | NPI | - | NPPES |
| 18833 | Medicaid | ND |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 7481 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Home Care | Mandan, ND | Home health agency |
| Sanford Medical Center Bismarck | Bismarck, ND | Hospital |
| Chi St Alexius Health | Bismarck, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Bismarck | 9739098575 | 448 |
| St Alexius Medical Center | 8426960865 | 205 |
News Archive
Shire plc, the global specialty biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion on the marketing authorisation for VPRIV (velaglucerase alfa), the company's enzyme replacement therapy for the treatment of type 1 Gaucher disease.
Personalized Immunotherapy for Tumor Diseases and Beyond introduces personalized immunotherapy with multi-dimensional models of analysis to determine the best plan for the immunotherapy of patients.
A new study published in the August 2010 journal, Appetite, further demonstrates that people who consume low-calorie sweeteners are able to significantly reduce their caloric intake and do not overeat.In fact, study participants who received the sugar substitutes instead of sugar consumed significantly fewer calories and there was no difference in hunger levels despite having fewer calories overall.
The Health Innovation Campus at Lancaster University has brought together a taskforce of experts for a major investigation into the prevalence of cancer in the region, to help improve early detection and save lives.
The US Food and Drug Administration has granted marketing approval to GlaxoSmithKline's new type 2 diabetes drug, branded Tanzeum in the US and Eperzan in Europe, which uses Novozymes' Veltis technology to achieve an extended half-life that means patients are only required to inject their medication once a week.
› Verified 2 days ago
| Entity Name | St Alexius Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205868429 PECOS PAC ID: 8426960865 Enrollment ID: O20031104000146 |
News Archive
Shire plc, the global specialty biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion on the marketing authorisation for VPRIV (velaglucerase alfa), the company's enzyme replacement therapy for the treatment of type 1 Gaucher disease.
Personalized Immunotherapy for Tumor Diseases and Beyond introduces personalized immunotherapy with multi-dimensional models of analysis to determine the best plan for the immunotherapy of patients.
A new study published in the August 2010 journal, Appetite, further demonstrates that people who consume low-calorie sweeteners are able to significantly reduce their caloric intake and do not overeat.In fact, study participants who received the sugar substitutes instead of sugar consumed significantly fewer calories and there was no difference in hunger levels despite having fewer calories overall.
The Health Innovation Campus at Lancaster University has brought together a taskforce of experts for a major investigation into the prevalence of cancer in the region, to help improve early detection and save lives.
The US Food and Drug Administration has granted marketing approval to GlaxoSmithKline's new type 2 diabetes drug, branded Tanzeum in the US and Eperzan in Europe, which uses Novozymes' Veltis technology to achieve an extended half-life that means patients are only required to inject their medication once a week.
› Verified 2 days ago
| Entity Name | Sanford Bismarck |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811941172 PECOS PAC ID: 9739098575 Enrollment ID: O20031105000403 |
News Archive
Shire plc, the global specialty biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion on the marketing authorisation for VPRIV (velaglucerase alfa), the company's enzyme replacement therapy for the treatment of type 1 Gaucher disease.
Personalized Immunotherapy for Tumor Diseases and Beyond introduces personalized immunotherapy with multi-dimensional models of analysis to determine the best plan for the immunotherapy of patients.
A new study published in the August 2010 journal, Appetite, further demonstrates that people who consume low-calorie sweeteners are able to significantly reduce their caloric intake and do not overeat.In fact, study participants who received the sugar substitutes instead of sugar consumed significantly fewer calories and there was no difference in hunger levels despite having fewer calories overall.
The Health Innovation Campus at Lancaster University has brought together a taskforce of experts for a major investigation into the prevalence of cancer in the region, to help improve early detection and save lives.
The US Food and Drug Administration has granted marketing approval to GlaxoSmithKline's new type 2 diabetes drug, branded Tanzeum in the US and Eperzan in Europe, which uses Novozymes' Veltis technology to achieve an extended half-life that means patients are only required to inject their medication once a week.
› Verified 2 days ago
| Entity Name | Sanford Medical Center Fargo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184917924 PECOS PAC ID: 8426967803 Enrollment ID: O20110331000495 |
News Archive
Shire plc, the global specialty biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion on the marketing authorisation for VPRIV (velaglucerase alfa), the company's enzyme replacement therapy for the treatment of type 1 Gaucher disease.
Personalized Immunotherapy for Tumor Diseases and Beyond introduces personalized immunotherapy with multi-dimensional models of analysis to determine the best plan for the immunotherapy of patients.
A new study published in the August 2010 journal, Appetite, further demonstrates that people who consume low-calorie sweeteners are able to significantly reduce their caloric intake and do not overeat.In fact, study participants who received the sugar substitutes instead of sugar consumed significantly fewer calories and there was no difference in hunger levels despite having fewer calories overall.
The Health Innovation Campus at Lancaster University has brought together a taskforce of experts for a major investigation into the prevalence of cancer in the region, to help improve early detection and save lives.
The US Food and Drug Administration has granted marketing approval to GlaxoSmithKline's new type 2 diabetes drug, branded Tanzeum in the US and Eperzan in Europe, which uses Novozymes' Veltis technology to achieve an extended half-life that means patients are only required to inject their medication once a week.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sean S Russell, MD Po Box 5501, Bismarck, ND 58506-5501 Ph: (701) 323-6000 | Sean S Russell, MD 222 N 7th St, Bismarck, ND 58501-4436 Ph: (701) 323-6000 |
News Archive
Shire plc, the global specialty biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion on the marketing authorisation for VPRIV (velaglucerase alfa), the company's enzyme replacement therapy for the treatment of type 1 Gaucher disease.
Personalized Immunotherapy for Tumor Diseases and Beyond introduces personalized immunotherapy with multi-dimensional models of analysis to determine the best plan for the immunotherapy of patients.
A new study published in the August 2010 journal, Appetite, further demonstrates that people who consume low-calorie sweeteners are able to significantly reduce their caloric intake and do not overeat.In fact, study participants who received the sugar substitutes instead of sugar consumed significantly fewer calories and there was no difference in hunger levels despite having fewer calories overall.
The Health Innovation Campus at Lancaster University has brought together a taskforce of experts for a major investigation into the prevalence of cancer in the region, to help improve early detection and save lives.
The US Food and Drug Administration has granted marketing approval to GlaxoSmithKline's new type 2 diabetes drug, branded Tanzeum in the US and Eperzan in Europe, which uses Novozymes' Veltis technology to achieve an extended half-life that means patients are only required to inject their medication once a week.
› Verified 2 days ago
Dr. Ling Sing Chow, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 900 E Broadway Ave, Bismarck, ND 58501 Phone: 701-530-7000 | |
Nicholas C Mahr, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 310 N 10th Street, Bismarck, ND 58501 Phone: 701-530-7500 Fax: 701-530-7484 | |
Dr. Maria Susana Castejon Welchez, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 300 N 7th St, Bismarck, ND 58501 Phone: 701-323-6000 | |
Dr. Sharmaine Habib, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 300 N 7th St, Bismarck, ND 58501 Phone: 701-323-8121 | |
Agnieszka Olga Solberg, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 900 E Broadway Ave, Bismarck, ND 58501 Phone: 701-530-7000 | |
Amy Marie Kaminski, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 900 E Broadway Ave, Bismarck, ND 58501 Phone: 701-530-7000 | |
Ivaldo A Lunardi, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 222 N 7th St, Bismarck, ND 58501 Phone: 701-323-6000 Fax: 701-323-5709 |